APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline.
Level 3 - non-randomized controlled study
Prospective observational cohort study evaluating biomarker-stratified cognitive decline
PubMed 32376954 · doi:10.1038/s41586-020-2247-3
What was done
Human participants were evaluated to compare blood-brain barrier (BBB) integrity in the hippocampus and medial temporal lobe between APOE4 carriers (ε3/ε4 or ε4/ε4) and non-carriers (ε3/ε3), spanning cognitively unimpaired and impaired states. BBB breakdown was assessed in relation to cerebrospinal fluid (CSF) and PET measures of amyloid-β and tau pathology. Baseline CSF levels of the pericyte injury marker soluble PDGFRβ and cyclophilin A-matrix metalloproteinase-9 pathway activity were tested as predictors of prospective cognitive decline controlling for amyloid-β and tau status.
What was found
The abstract reports no numerical values, effect sizes, or confidence intervals. Directionally, APOE4 carriers exhibited elevated BBB breakdown in the hippocampus and medial temporal lobe relative to non-carriers; this was evident in unimpaired individuals and worsened in those with cognitive impairment, independent of amyloid-β and tau. High baseline CSF soluble PDGFRβ predicted future cognitive decline in APOE4 carriers but not in non-carriers after adjusting for Alzheimer's pathology, and correlated with elevated cyclophilin A-matrix metalloproteinase-9 pathway activity.
Why it matters
This study shows that APOE4 drives pericyte degeneration and BBB breakdown that contributes to cognitive impairment independently of classic amyloid and tau pathways. This identifies the cyclophilin A-matrix metalloproteinase-9 cascade and BBB pericytes as distinct therapeutic targets for APOE4 carriers.
Limits
The abstract does not state the sample size, cohort demographics, duration of follow-up, or quantitative effect estimates. As an observational study, it cannot definitively prove that BBB breakdown causes cognitive decline rather than acting as a co-occurring marker of neurodegeneration.
Cited by
- supports Breakdown of the blood-brain barrier is emerging as one of the earliest signs of dementia.